GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Cash Flow from Investing

Medigen Biotechnology (ROCO:3176) Cash Flow from Investing : NT$2,917 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Medigen Biotechnology spent NT$14 Mil on purchasing property, plant, equipment. It gained NT$0 Mil from selling property, plant, and equipment. It spent NT$0 Mil on purchasing business. It gained NT$0 Mil from selling business. It spent NT$-2,252 Mil on purchasing investments. It gained NT$0 Mil from selling investments. It paid NT$1Mil for net Intangibles purchase and sale. And it paid NT$189 Mil for other investing activities. In all, Medigen Biotechnology gained NT$2,047 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Medigen Biotechnology Cash Flow from Investing Historical Data

The historical data trend for Medigen Biotechnology's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Cash Flow from Investing Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 446.53 -237.09 -910.50 -2,453.12 497.66

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -371.57 107.43 -30.59 792.39 2,047.47

Medigen Biotechnology Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Medigen Biotechnology's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Medigen Biotechnology's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2,917 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology  (ROCO:3176) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Medigen Biotechnology's purchase of property, plant, equipment for the three months ended in Mar. 2024 was NT$-14 Mil. It means Medigen Biotechnology spent NT$14 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Medigen Biotechnology's sale of property, plant, equipment for the three months ended in Mar. 2024 was NT$0 Mil. It means Medigen Biotechnology gained NT$0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Medigen Biotechnology's purchase of business for the three months ended in Mar. 2024 was NT$0 Mil. It means Medigen Biotechnology spent NT$0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Medigen Biotechnology's sale of business for the three months ended in Mar. 2024 was NT$0 Mil. It means Medigen Biotechnology gained NT$0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Medigen Biotechnology's purchase of investment for the three months ended in Mar. 2024 was NT$2,252 Mil. It means Medigen Biotechnology spent {stock_data.stock.currency_symbol}}-2,252 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Medigen Biotechnology's sale of investment for the three months ended in Mar. 2024 was NT$0 Mil. It means Medigen Biotechnology gained NT$0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Medigen Biotechnology's net Intangibles purchase and sale for the three months ended in Mar. 2024 was NT$-1 Mil. It means Medigen Biotechnology paid NT$1 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Medigen Biotechnology's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0 Mil. It means Medigen Biotechnology paid NT$0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Medigen Biotechnology's cash from other investing activities for the three months ended in Mar. 2024 was NT$-189 Mil. It means Medigen Biotechnology paid NT$189 Mil for other investing activities.


Medigen Biotechnology Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines